Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium

Journal of Steroid Biochemistry and Molecular Biology

Volumn 122, Issue 4, 2010, Pages 279-286

  Catherino, William H ^a,b   Malik, Minnie ^a   Driggers, Paul ^b   Chappel, Scott ^c   Segars, James ^a,b   Davis, Joseph ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c Tokai Pharmaceuticals Inc   (United States)

Author keywords

Apoptosis; Endometrium; Extracellular matrix; Leiomyoma; Myometrium; Selective progesterone receptor modulator

Indexed keywords

ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; CD 8947; CP 8863; CP 8947; ESTROGEN RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR; MATRIX PROTEIN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; PROTEIN COL1A1; PROTEIN COL7A1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CP8863; INDOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG STRUCTURE; ENDOMETRIUM; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MYOMETRIUM; NONHUMAN; PROTEIN EXPRESSION; RABBIT; UTERUS MYOMA; ANIMAL; DRUG EFFECTS; LEIOMYOMA; METABOLISM; TUMOR CELL LINE; UTERINE NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIUM; FEMALE; HUMANS; INDOLES; LEIOMYOMA; MYOMETRIUM; RABBITS; RECEPTORS, PROGESTERONE; UTERINE NEOPLASMS;

ORYCTOLAGUS CUNICULUS;

EID: 77957272596     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.05.005     Document Type: Article

References (42)

1. Day Baird D., Dunson M.B., Hill M.C., Cousins D., Schectman J.M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am. J. Obstet. Gynecol. 2003, 188:100-107.
2. Benecke C., Kruger T.F., Siebert T.I., Van der Merwe J.P., Steyn D.W. Effect of leiomyomas on fertility in patients undergoing assisted reproduction. Gynecol. Obstet. Invest. 2005, 59:225-230.
3. Sheiner E., Bashiri A., Levy A., Hershkovitz R., Katz M., Mazor M. Obstetric characteristics and perinatal outcome of pregnancies with uterine leiomyomas. J. Reprod. Med. 2004, 49:182-186.
4. Wegienka G., Baird D.D., Hertz-Picciotto I., Harlow S.D., Steege J.F., Hill M.C., Schectman J.M., Hartmenn K.E. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet. Gynecol. 2003, 101:431-437.
5. Farquhar C.M., Steiner C.A. Hysterectomy rates in the United States 1990-1997. Obstet. Gynecol. 2002, 99:229-234.
6. Marshburn P.B., Matthews M.L., Hurst B.S. Uterine artery embolization as a treatment option for uterine myomas. Obstet. Gynecol. Clin. North Am. 2006, 33:125-144.
7. Hindley J., Gedroyc W.M., Regan L., Stewart E., Tempany C., Hynnen K., MacDanold N., Inbar Y., Itzchak Y., Rabinovici J., Kim K., Geschwind J.F. MRI guidance of focused ultrasound therapy of uterine leiomyomas: early results. Am. J. Roentgenol. 2004, 183:1713-1719.
8. Olufowobi O., Sharij K., Papaionnou S., Neelakantan D., Mohammed H., Afnan M. Are the anticipated benefits of myomectomy achieved in women of reproductive age?. J. Obstet. Gynaecol. 2004, 24:434-440.
9. Buttram V.C., Reiter R.C. Uterine leiomyomata: etiology, symptomatology, and management. Fertil. Steril. 1981, 36:433-445.
10. Carbonell Esteve J.L, Acosta R., Heredia B., Perez Y., Castaneda M.C.Y., Hernandez A.V. Mifepristone for the treatment of uterine leiomyomas. Obstet. Gynecol. 2008, 112:1029-1036.
11. Eisinger S.H., Meldrum S., Fiscella K., le Roux H.D., Guzick D.S. Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol. 2003, 101:243-250.
12. Attardi B., Burgenson J., Hild S., Reel J. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 2004, 88:277-288.
13. Attardi B, Burgenson J., Hild S., Reel J., Blye R. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol. Cell. Endocrinol. 2002, 188:111-123.
14. Levens E.D., Potlog-Nahari C., Armstrong A.Y., Wesley R., Premkumar A., Blithe D.L., Blocker W., Nieman L.K. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet. Gynecol. 2008, 111:1129-1136.
15. Chwalisz K., Perez M.C., DeManno D., Winkel C., Schubert G., Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr. Rev. 2005, 267:423-438.
16. Williams A.R., Critchley H.O., Osei J., Ingamells S., Cameron I.T., Han C., Chwalisz K. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterus tissues after three months treatment in patients with symptomatic uterine leiomyomata. Hum. Reprod. 2007, 22:1696-1704.
17. Tabata Y., Hatsu M., Kurata Y., Miyajima K., Tani M., Sasaki T., Kodama Y., Tsuruoka T., Omoto S. PF1092A, B, and C, new nonsteroidal progesterone receptor ligands produced by Penicillium oblatum II. J. Antibiotics 1997, 50:309-313.
18. Tabata Y, Miike N., Hatsu M., Kurata Y., Yaguchi T., Someya A., Miyadoh S., Hoshiko S., Tsuruoka T., Omoto S. PF1092A, B, and C, new nonsteroidal progesterone receptor ligands produced by Penicillium oblatum I. J. Antibiotics 1997, 50:304-308.
19. Kurata Y., Tabata Y., Shinei R., Iizuka Y., Masuda N.T., Kurihara K., Okonogi T., Hoshiko S. Endocrinological properties of two novel nonsteroidal progesterone receptor modulators, CP8816 and CP8863. J. Pharmacol. Exp. Ther. 2005, 313:916-920.
20. Mori T., Kurata Y., Tabata Y., Niho N., Matsuda M., Zhou Y. Priming effects of novel nonsteroidal progesterone receptor modulators CP8816 and CP8863 on the development of adenomyosis in the mouse uterus. Life Sci. 2002, 71:527-535.
21. Catherino W.H., Leppert P.C., Stenmark M.H., Payson M., Nieman L.K., Segars J.H. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chrom. Cancer 2004, 40:204-217.
22. Malik M., Webb J., Catherino W.H. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin. Endocrinol. (Oxf.) 2008, 69:462-470.
23. Malik M., Catherino W.H. Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays. Fertil. Steril. 2007, 87:1166-1172.
24. Joseph D.S., Malik M., Nurudeen S., Catherino W.H. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil. Steril. 2010, 93:1153-1164.
25. Catherino W.H., Malik M. Uterine leiomyomas express a molecular pattern that lowers retinoic acid exposure. Fertil. Steril. 2007, 87:1388-1398.
26. Malik M., Mendoza M., Payson M., Catherino W.H., Curcumin a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression. Fertil. Steril. 2008, 91:2177-2184.
27. Madauss K.P, Grygielko E.T., Deng S.J., Sulpizio A.C., Stanley T.B., Wu C., Short S.A., Thompson S.K., Stewart E.L., Laping N.J., Williams S.P., Bray J.D. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol. Endocrinol. 2007, 21:1066-1081.
28. McPhail M.K. The assay of progestin. J. Physiol. 1934, 83:145-156.
29. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
30. Leppert P.C., Baginski T., Prupas C., Catherino W.H., Pletcher S., Segars J.H. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil. Steril. 2004, 82:1182-1187.
31. Nakamura Y., Yoshimura Y., Yamada H., Ubukata Y., Ando M., Suzuki M. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist. Fertil. Steril. 1991, 55:900-905.
32. Felberbaum R.E., Germer U., Ludwig M., Riethmuller-Winzen H., Heise S., Buttge I., Bauer O., Reissmann T., Engel J., Diedrich K. Treatment of uterine leiomyomas with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum. Reprod. 1998, 13:1660-1668.
33. Watanabe Y., Nakamura G., Matsuguchi H., Nozaki M., Sano M., Nakano H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil. Steril. 1992, 58:66-71.
34. Bianchi S., Fedele L., Vignali M., Galbiati E., Cherubini R., Ortolani S. Effects on bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas. Calcif. Tissue Int. 1995, 57:78-80.
35. Freundl G., Gödtke K., Gnoth C., Godehardt E., Kienle R. Steroidal 'add back' therapy in patients treated with GnRH agonists. Gyn. Obstet. Invest. 1998, 45:22-30.
36. DiSorbo D., Rosen F., McPartland R.P., Milholland R.J. Glucocorticoid activity of various progesterone analogs: correlation between specific binding in thymus and liver and biologic activity. Ann. N.Y. Acad. Sci. 1977, 286:355-368.
37. Pesonen U., Koulu M., Heikinheimo O., Huupponen R. The glucocorticoid antagonist mifepristone reveals abnormal regulation of the adrenocortical system in obese Zucker rats. J. Endocrinol. 1992, 132:425-431.
38. Ferenczy A., Gelfand M.M., Tzipris F. The cytodynamics of endometrial hyperplasia and carcinoma: a review. Ann. Pathol. 1983, 3:189-201.
39. Frydman R., Belaisch-Allart J., Parneix I., Forman R., Hazout A., Testart J. Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program. Fertil. Steril. 1988, 50:471-475.
40. Lerner L.J., Jordan V.C. Development of antiestrogens and their use in breast cancer: eighth Cain Memorial award lecture. Cancer Res. 1990, 50:4177-4189.
41. Friedl A., Jordan V.C. What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res. Treat. 1994, 31:27-39.
42. McDonnell D.P., Wijavaratne A., Chang C.Y., Norris J.D. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am. J. Cardiol. 2002, 90:35F-43F.